Incidence and Risk Factors of Active Tuberculosis Among Hospitalized Patients with Latent Tuberculosis Infection in China: A Cohort Study

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2024 Mar 18

PMID 38495623

Authors

Ye Liu

Lifan Zhang

Yan Chen

Guiren Ruan

Yuchen Liu

Shi Chen

Lantian Xie

Fengying Wu

Xiaochun Shi

Xiaoqing Liu

Affiliations

Soon will be listed here.

Abstract

Background: The population with latent tuberculosis infection (LTBI) represents a potential pool of patients with active tuberculosis (ATB). T-SPOT.TB is an important test tool for screening LTBI. Owing to the large population of LTBI patients in China, it is necessary to identify a high-risk group for LTBI and enlarge tuberculosis preventive treatment (TPT) to reduce the incidence of ATB.

Methods: Hospitalized patients with positive T-SPOT.TB results were recruited from January 2013 to December 2016. Patients with ATB were excluded. Basic information was collected and the development of ATBs was examined during follow-up. The life-table method was used to calculate cumulative incidence rates. Potential risk factors were analyzed through Cox regression analysis.

Results: A total of 1680 patients with LTBI were recruited in the follow-up cohort, and 377 (22.44%) patients dropped out. With a median follow-up time of 81 months [interquartile range (IQR):61-93], 19 of 1303 patients with LTBI developed ATB. The 1-year incidence of ATB was 614 per 100,000 individuals [95%confidence interval (95% CI):584-644]. Over 5-year period, the cumulative incidence of ATB was 1496 per 100,000 [95% CI:1430-1570], and the incidence density was 240 per 100,000 person-years[95% CI:144-375]. In the Cox regression model, exposure of pulmonary tuberculosis (PTB) [adjusted hazard ratio (aHR)=10.557, 95% CI:2.273-49.031], maximum daily dosage of glucocorticoids (GCs)≥ 50 mg/d (aHR=2.948, 95% CI:1.122-7.748), leflunomide (LEF) treatment (aHR=8.572, 95% CI:2.222 -33.070), anemia (aHR=2.565, 95% CI:1.015-6.479) and T-SPOT.TB level≥300SFCs/10 PBMCs (aHR=4.195, 95% CI:1.365-12.892) were independent risk factors for ATB development in LTBI patients.

Conclusion: The incidence of ATB is significantly higher in hospitalized patients with LTBI than in the general population. The exposure history of PTB, maximum daily dosage of GCs≥ 50 mg/day, LEF treatment, anemia, and T-SPOT.TB level≥300SFCs/10PBMCs, were the risk factors of tuberculosis reactivation. Hospitalized LTBI patients with the above factors may need TPT.

References

Long W, Cai F, Wang X, Zheng N, Wu R . High risk of activation of latent tuberculosis infection in rheumatic disease patients. Infect Dis (Lond). 2019; 52(2):80-86. DOI: 10.1080/23744235.2019.1682187. View

Shah M, Dorman S . Latent Tuberculosis Infection. N Engl J Med. 2021; 385(24):2271-2280. DOI: 10.1056/NEJMcp2108501. View

Campbell J, Winters N, Menzies D . Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020; 368:m549. PMC: 7190060. DOI: 10.1136/bmj.m549. View

Bagcchi S . WHO's Global Tuberculosis Report 2022. Lancet Microbe. 2022; 4(1):e20. DOI: 10.1016/S2666-5247(22)00359-7. View

Ledesma J, Ma J, Zheng P, Ross J, Vos T, Kyu H . Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis. BMC Infect Dis. 2021; 21(1):467. PMC: 8141158. DOI: 10.1186/s12879-021-06141-4. View

Breedveld F, Dayer J . Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000; 59(11):841-9. PMC: 1753034. DOI: 10.1136/ard.59.11.841. View

Cantini F, Niccoli L, Capone A, Petrone L, Goletti D . Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019; 18(5):415-425. DOI: 10.1080/14740338.2019.1612872. View

Herrmann J, Belloy M, Porcher R, Simonney N, AbouTaam R, Lebourgeois M . Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS One. 2009; 4(1):e4130. PMC: 2607538. DOI: 10.1371/journal.pone.0004130. View

Lee S, Kang Y, Yoon Y, Um S, Lee S, Yoo C . The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci. 2006; 21(6):1028-32. PMC: 2721923. DOI: 10.3346/jkms.2006.21.6.1028. View

10.

Kang Y, Park H, Park S, Kim J, Lee J, Kim J . Combined analysis of whole blood interferon gamma release assay and complete blood count analysis for rapid discrimination of active tuberculosis and latent tuberculosis infection. J Clin Tuberc Other Mycobact Dis. 2021; 24:100253. PMC: 8262775. DOI: 10.1016/j.jctube.2021.100253. View

11.

Comstock G, LIVESAY V, Woolpert S . The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974; 99(2):131-8. DOI: 10.1093/oxfordjournals.aje.a121593. View

12.

Kang W, Wang G, Wu M, Yang K, Er-Tai A, Wu S . Interferon-Gamma Release Assay is Not Appropriate for the Diagnosis of Active Tuberculosis in High-Burden Tuberculosis Settings: A Retrospective Multicenter Investigation. Chin Med J (Engl). 2018; 131(3):268-275. PMC: 5798046. DOI: 10.4103/0366-6999.223860. View

13.

Cain D, Cidlowski J . Immune regulation by glucocorticoids. Nat Rev Immunol. 2017; 17(4):233-247. PMC: 9761406. DOI: 10.1038/nri.2017.1. View

14.

Ai J, Ruan Q, Liu Q, Zhang W . Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016; 5:e10. PMC: 4777925. DOI: 10.1038/emi.2016.10. View

15.

Zhang L, Zou X, Jiang N, Xie L, Liu J, Yang Z . Incidence and risk factors of tuberculosis in systemic lupus erythematosus patients: a multi-center prospective cohort study. Front Immunol. 2023; 14:1157157. PMC: 10304284. DOI: 10.3389/fimmu.2023.1157157. View

16.

Getahun H, Matteelli A, Chaisson R, Raviglione M . Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015; 372(22):2127-35. DOI: 10.1056/NEJMra1405427. View

17.

Xie Y, Xie J, Meijer A, Schaaf M . Glucocorticoid-Induced Exacerbation of Mycobacterial Infection Is Associated With a Reduced Phagocytic Capacity of Macrophages. Front Immunol. 2021; 12:618569. PMC: 8148013. DOI: 10.3389/fimmu.2021.618569. View

18.

Gao L, Li X, Liu J, Wang X, Lu W, Bai L . Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017; 17(10):1053-1061. DOI: 10.1016/S1473-3099(17)30402-4. View

19.

VanValkenburg A, Kaipilyawar V, Sarkar S, Lakshminarayanan S, Cintron C, Prakash Babu S . Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis. Front Immunol. 2022; 13:1011166. PMC: 9554585. DOI: 10.3389/fimmu.2022.1011166. View

20.

Landry J, Menzies D . Preventive chemotherapy. Where has it got us? Where to go next?. Int J Tuberc Lung Dis. 2008; 12(12):1352-64. View